Mckesson Corp Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Margins
| Current | |
|---|---|
| Gross Margin | 3.6% |
| EBITDA Margin | 1.8% |
| Operating Margin | 1.6% |
| Net Margin | 1.1% |
Returns
Balance Sheet Health
Quality Metrics
Multi-Year Trend
Dividend
Capital Allocation
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| North American Pharmaceutical | $336.7B | +11.0% | View detailsFor fiscal 2027, McKesson expects North American Pharmaceutical segment revenue growth of 4.0% to 8.0% and operating profit growth of 5.5% to 9.5%. |
| Oncology & Multispecialty | $48.4B | +31.0% | View detailsFor fiscal 2027, McKesson expects Oncology & Multispecialty segment revenue growth of 14.5% to 18.5% and adjusted operating profit growth of 13.5% to 17.5%, and reaffirmed its long-term adjusted segment operating profit growth target of 13% to 16% for the segment. |
| Prescription Technology Solutions | $5.8B | +11.0% | View detailsFor fiscal 2027, McKesson expects Prescription Technology Solutions segment revenue growth of 2.5% to 6.5% and operating profit growth of 11.0% to 15.0%. |
| Medical-Surgical Solutions | $11.5B | +1.0% | View detailsFor fiscal 2027, McKesson expects Medical-Surgical Solutions segment revenue growth of 1.0% to 6.0% and operating profit growth of flat to 4.0%. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.